Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Ocuphire Pharma, Inc. OCUP NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
51/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Ocuphire Pharma, Inc. (OCUP) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 5 Buy.

OCUP Analyst Ratings

Buy
5
Ratings
5 Buy
Based on 5 analysts giving stock ratings to Ocuphire Pharma, Inc. in the past 3 months
Rating breakdown
Buy
5 100%
100%
Buy
5 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

KOD
KOD
Kodiak Sciences Inc.
$45.07
+7.44%
 CTIC
CTIC
CTI BioPharma Corp.
$9.10
+0.06%
 EYPT
EYPT
EyePoint Pharmaceuticals, Inc.
$14.34
-1.24%
 SLS
SLS
SELLAS Life Sciences Group, Inc.
$4.86
+2.10%
 RIGL
RIGL
Rigel Pharmaceuticals, Inc.
$31.39
+4.74%
 CKPT
CKPT
Checkpoint Therapeutics, Inc.
$4.26
+0.00%
 PLX
PLX
Protalix BioTherapeutics, Inc.
$2.36
+3.06%
 FBIOP
FBIOP
Fortress Biotech, Inc.
$13.37
-2.33%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message